| Open: | 0.95 | High: | 0.97 | | Low: | 0.922 | Volume: | 1,965,521 | | Yield: | n/a | P/E Ratio: | n/a | | Bid: | n/a | Ask: | n/a | | Ex Div. Date: | n/a | Ex Div. Amount: | n/a |
| Overview: |
CytRx Corporation as (CytRx) is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, specializing in oncology. Its drug development pipeline includes clinical development of three product candidates for cancer indications, including three planned Phase II clinical trials for INNO-206 as a treatment for pancreatic cancer, gastric (stomach) cancer and soft tissue sarcomas, two Phase II proof-of-concept clinical trials with bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL) and patients with glioblastoma multiforme, and a registration study of tamibarotene for the treatment of acute promyelocytic leukemia (APL). In addition to its oncology programs, it is developing two drug candidates based on its molecular chaperone regulation technology. In February 2009, a Phase II/III adaptive clinical trial commenced to study arimoclomol in a subset of patients with the inherited or familial form ALS.
More from Reuters »
|
| Contact: |
No information available. |
Spam Report:  |
1 possible spam reported.
Latest spam reported on 09-10-2006
[ view the detailed CYTR spam report ] |
|
Subscribe to our newsletter to get free stock market tips and investment advice! (348 subscribers)
RSS Feed
XHTML
RSS